688235 百济神州
午间休市 07-24 11:29:58
资讯
新帖
简况
百济神州(06160)涨3.92% 拟追加投资3亿美元扩建美国生产基地和临床研发中心
金吾财讯 · 09:59
百济神州(06160)涨3.92% 拟追加投资3亿美元扩建美国生产基地和临床研发中心
百济神州/安进 FIC 双抗，皮下制剂进入 III 期
新浪医药 · 07-23 19:30
百济神州/安进 FIC 双抗，皮下制剂进入 III 期
百济神州拟追加投资3亿美元 扩建其位于新泽西州的美国研发与生产中心 - 公司声明
美股速递 · 07-23 18:46
百济神州拟追加投资3亿美元 扩建其位于新泽西州的美国研发与生产中心 - 公司声明
百济神州追加3亿美元投资扩大美国生产布局
格隆汇 · 07-23 18:45
百济神州追加3亿美元投资扩大美国生产布局
百济神州加码美国制造，总投资超10亿美元以推进创新癌症药物
美股速递 · 07-23 18:02
百济神州加码美国制造，总投资超10亿美元以推进创新癌症药物
百济神州汪来：公司的背水一战，研发做了这些事
第一财经 · 07-23 12:05
百济神州汪来：公司的背水一战，研发做了这些事
7月21日百济神州涨6.25%，创新药ETF银华基金重仓该股
证券之星 · 07-21 16:35
7月21日百济神州涨6.25%，创新药ETF银华基金重仓该股
百济神州涨6.25%，中邮证券二个月前给出“买入”评级
证券之星 · 07-21 16:35
百济神州涨6.25%，中邮证券二个月前给出“买入”评级
每周股票复盘：百济神州（688235）将召开2026Q2业绩电话会
证券之星 · 07-19
每周股票复盘：百济神州（688235）将召开2026Q2业绩电话会
7月17日百济神州跌7.81%，万家行业优选LOF基金重仓该股
证券之星 · 07-17
7月17日百济神州跌7.81%，万家行业优选LOF基金重仓该股
美股盘前中概股涨跌互现，理想汽车、百济神州涨3%
每日经济新闻 · 07-13
美股盘前中概股涨跌互现，理想汽车、百济神州涨3%
每周股票复盘：百济神州（688235）授出43.4万股受限股份
证券之星 · 07-12
每周股票复盘：百济神州（688235）授出43.4万股受限股份
百济神州(06160)授出合共3.34万股美国存托股份受限制股份单位
智通财经 · 07-08
百济神州(06160)授出合共3.34万股美国存托股份受限制股份单位
百济神州：截至2026年3月31日股东户数为35,393户
证券之星 · 07-07
百济神州：截至2026年3月31日股东户数为35,393户
【券商聚焦】华福证券首予百济神州(06160)“买入”评级 指公司迈入多曲线增长新纪元
金吾财讯 · 07-07
【券商聚焦】华福证券首予百济神州(06160)“买入”评级 指公司迈入多曲线增长新纪元
每周股票复盘：百济神州（688235）百悦泽临床研究达主要终点
证券之星 · 07-05
每周股票复盘：百济神州（688235）百悦泽临床研究达主要终点
港股异动 | 百济神州(06160)早盘涨超4% MANGROVE 3期临床研究取得积极结果 计划下半年进行申报
智通财经 · 07-03
港股异动 | 百济神州(06160)早盘涨超4% MANGROVE 3期临床研究取得积极结果 计划下半年进行申报
百济神州补税风波：刚“摘U”即遇4.46亿元追缴，逾20家药企卷入，医药合规进入刚性时代
华夏时报网 · 07-01
百济神州补税风波：刚“摘U”即遇4.46亿元追缴，逾20家药企卷入，医药合规进入刚性时代
百济神州最新公告：公司产品百悦泽3期临床研究取得积极结果
证券之星 · 06-30
百济神州最新公告：公司产品百悦泽3期临床研究取得积极结果
百济神州将公布Mangrove研究完整数据 计划于2026年下半年提交全球监管申请
美股速递 · 06-30
百济神州将公布Mangrove研究完整数据 计划于2026年下半年提交全球监管申请
加载更多
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":274.45,"timestamp":1784863798000,"preClose":272.45,"halted":0,"volume":3602418,"delay":0,"changeRate":0.0073,"floatShares":114999999,"shares":1541000000,"eps":2.0521,"marketStatus":"午间休市","change":2,"latestTime":"07-24 11:29:58","open":271.94,"high":282.97,"low":271.72,"amount":998000000,"amplitude":0.0413,"askPrice":274.45,"askSize":10,"bidPrice":274.02,"bidSize":2,"shortable":0,"etf":0,"ttmEps":2.0521,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784869200000},"marketStatusCode":3,"adr":0,"adjPreClose":272.45,"symbolType":"stock_kcb","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":299.7,"lowLimit":245.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1541419108,"isCdr":false,"pbRate":12.71,"roa":"--","peRate":133.741046,"roe":"5.05%","epsLYR":1.03,"committee":-0.333333,"marketValue":423042000000,"turnoverRate":0.0313,"status":0,"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":199.6,"timestamp":1784865900006,"preClose":193.8,"halted":0,"volume":2161517,"delay":0,"premium":"-37.14"},"floatMarketCap":31577000000},"requestUrl":"/m/hq/s/688235/","defaultTab":"news","newsList":[{"id":"2653701077","title":"百济神州(06160)涨3.92% 拟追加投资3亿美元扩建美国生产基地和临床研发中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2653701077","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653701077?lang=zh_cn&edition=full","pubTime":"2026-07-24 09:59","pubTimestamp":1784858358,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 日内震荡走高，盘中最高触及202.400港元，最新为201.400港元，涨幅3.92%，成交额1.71亿港元。消息面上，7月23日，百济神州宣布将追加投资3亿美元，扩建位于美国新泽西州霍普韦尔普林斯顿西部创新园区的旗舰生产基地和临床研发中心，新增小分子药物生产能力，完善公司全球化生产和供应体系。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NDE0ZmVkNmQ0OWQ1YWQ5ZWU5ODBlOTBjYzlmMjcxMzI0MDU1NzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986671","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1251922891.USD","LU1719994722.HKD","BK1588","BK1161","LU0307460666.USD","BK0239","BK4526","ONC","BK4585","LU1303224171.USD","BK1583","LU2328871848.SGD","LU1969619763.USD","LU1770034418.SGD","688235","BK1500","BK4588","KURE","LU0588546209.SGD","06160","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653074709","title":"百济神州/安进 FIC 双抗，皮下制剂进入 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653074709","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653074709?lang=zh_cn&edition=full","pubTime":"2026-07-23 19:30","pubTimestamp":1784806200,"startTime":"0","endTime":"0","summary":"7 月 22 日，药物临床试验登记与信息公示平台显示，安进和百济神州共同登记了一项在接受含铂一线化疗后的复发性广泛期小细胞肺癌试验参与者中比较 Tarlatamab皮下给药与静脉给药的 III 期研究DeLLphi-315。在皮下剂型的开发方面，安进和百济神州于 2024 年 9 月启动了一项在广泛期小细胞肺癌受试者中评价 Tarlatamab 皮下给药的安全性、耐受性、药代动力学和初步抗肿瘤活性的 Ib 期研究 DeLLphi-308。而本次启动的DeLLphi-315 研究是塔拉妥单抗皮下给药方案启动的首个 III 期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-23/doc-iniivazc5268721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06160","III","BK1500","BK4534","LU0868494617.USD","IE00B4R5TH58.HKD","ONC","LU0588546209.SGD","BK4134","IBBQ","LU1571399168.USD","LU1983299246.USD","LU2242652126.USD","SG9999001440.SGD","BK4139","BK1588","LU0307460666.USD","LU1969619763.USD","BK1583","LU0889565916.HKD","BK4588","IE0009355771.USD","688235","IBB","AMGN","BK4585","TBXU","LU2328871848.SGD","LU1770034418.SGD","PBE","KURE","LU2242646821.SGD","LU1251922891.USD","BIB","LU2112291526.USD","LU2468319806.SGD","IE0002141913.USD","BBH","BK4599","IE00BFTCPJ56.SGD","LU0058720904.USD","LU0289739699.SGD","LU1303224171.USD","LU0122379950.USD","LU0320765992.SGD","BK4581","LU1061106388.HKD","LU1719994722.HKD","IE00BJT1NW94.SGD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177280040","title":"百济神州拟追加投资3亿美元 扩建其位于新泽西州的美国研发与生产中心 - 公司声明","url":"https://stock-news.laohu8.com/highlight/detail?id=1177280040","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177280040?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:46","pubTimestamp":1784803586,"startTime":"0","endTime":"0","summary":"根据公司声明，生物制药企业百济神州计划额外投入3亿美元，用于扩建其设在美国新泽西州的研发与生产中心。此项投资旨在进一步强化公司在当地的研发能力并扩大生产规模。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653490457","title":"百济神州追加3亿美元投资扩大美国生产布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2653490457","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653490457?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:45","pubTimestamp":1784803543,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1969619763.USD","688235","LU1719994722.HKD","LU2328871848.SGD","KURE","LU1303224171.USD","LU1770034418.SGD","BK1588","BK0239","BK1583","06160","LU0307460666.USD","LU1251922891.USD","BK1500","LU0588546209.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162344869","title":"百济神州加码美国制造，总投资超10亿美元以推进创新癌症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1162344869","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162344869?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:02","pubTimestamp":1784800952,"startTime":"0","endTime":"0","summary":"百济神州宣布将扩大其在美国的生产制造能力，总投资额超过10亿美元，旨在加速其创新癌症药物的研发与商业化进程。此举标志着该公司在全球生物制药产业布局中迈出了关键一步，通过强化本土化生产，有望提升供应链韧性并更高效地服务美国及全球市场。新投资将用于建设或升级先进的生产设施，以支持其日益丰富的肿瘤治疗产品管线，满足未来临床与商业需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653715567","title":"百济神州汪来：公司的背水一战，研发做了这些事","url":"https://stock-news.laohu8.com/highlight/detail?id=2653715567","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653715567?lang=zh_cn&edition=full","pubTime":"2026-07-23 12:05","pubTimestamp":1784779520,"startTime":"0","endTime":"0","summary":"从2010年成立至今，百济神州（ONC.US、06160.HK、688235.SH）已成为A股市值最高的药企，这背后离不开旗下一款重磅药物BTK抑制剂泽布替尼的开发成功，这也是公司当前的“利润奶牛”来源。7月22日，在首届大国新药全球会议（CPIC2026）上，百济神州总裁、全球研发负责人汪来回顾了公司如何背水一战投入换来泽布替尼成功故事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233818666284.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233818666284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1303224171.USD","BK1500","BK1583","BK4139","LU1719994722.HKD","BK1161","BK0239","LU1969619763.USD","BK1588","LU2328871848.SGD","LU0588546209.SGD","KURE","LU1770034418.SGD","688235","ONC","BK4585","BK4526","06160","LU1251922891.USD","LU0307460666.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653220610","title":"7月21日百济神州涨6.25%，创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653220610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653220610?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:35","pubTimestamp":1784622941,"startTime":"0","endTime":"0","summary":"证券之星消息，7月21日百济神州涨6.25%，收盘报275.5元，换手率6.82%，成交量7.84万手，成交额20.67亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共31家，其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华目前规模为159.65亿元，最新净值0.871，较上一交易日上涨3.41%，近一年下跌0.9%。创新药ETF银华的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100030524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159316","LU0307460666.USD","LU2328871848.SGD","BK1500","06160","LU0588546209.SGD","LU1770034418.SGD","LU1969619763.USD","BK1588","688235","BK1583","LU1251922891.USD","LU1719994722.HKD","BK0239","KURE","LU1303224171.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653693220","title":"百济神州涨6.25%，中邮证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2653693220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653693220?lang=zh_cn&edition=full","pubTime":"2026-07-21 16:35","pubTimestamp":1784622932,"startTime":"0","endTime":"0","summary":"今日百济神州涨6.25%，收盘报275.5元。2026年5月13日，中邮证券研究员盛丽华,陈灿发布了对百济神州的研报《泽布替尼同比维持高增，全年业绩指引上调》，该研报对百济神州给出“买入”评级。公司为创新药出海龙头企业，全球商业化能力突出、在研管线即将进入收获期，维持“买入”评级。百济神州个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100030521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06160","161027","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652375562","title":"每周股票复盘：百济神州（688235）将召开2026Q2业绩电话会","url":"https://stock-news.laohu8.com/highlight/detail?id=2652375562","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652375562?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:06","pubTimestamp":1784394370,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，百济神州报收于250.51元，较上周的267.84元下跌6.47%。本周，百济神州7月15日盘中最高价报285.85元。百济神州当前最新总市值3861.41亿元，在化学制药板块市值排名1/149，在两市A股市值排名34/5199。本周关注点公司公告汇总：百济神州将于2026年8月5日召开第二季度业绩电话会议公司公告汇总百济神州有限公司将于2026年8月5日发布截至2026年6月30日止第二季度未经审计财务业绩及2026年半年度主要财务数据公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0239","688235","BK1161","LU1719994722.HKD","LU0307460666.USD","LU0588546209.SGD","LU1303224171.USD","KURE","LU1770034418.SGD","BK1588","BK1583","LU2328871848.SGD","06160","BK1500","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652405197","title":"7月17日百济神州跌7.81%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652405197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652405197?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:25","pubTimestamp":1784276712,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日百济神州跌7.81%，收盘报250.51元，换手率6.62%，成交量7.62万手，成交额19.33亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共107家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","LU1770034418.SGD","06160","BK1583","KURE","BK1161","LU1969619763.USD","BK1500","LU0588546209.SGD","BK0239","LU1719994722.HKD","160916","LU1251922891.USD","BK1588","LU1303224171.USD","LU0307460666.USD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651194918","title":"美股盘前中概股涨跌互现，理想汽车、百济神州涨3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194918","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651194918?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:04","pubTimestamp":1783929885,"startTime":"0","endTime":"0","summary":"7月13日，美股盘前中概股涨跌互现，理想汽车、百济神州涨3%，京东、网易涨2%，阿里巴巴涨0.6%，哔哩哔哩、拼多多、百度跌1%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607133803774313.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607133803774313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0553294199.USD","LU0173614495.USD","LU1880383366.USD","BK4563","LU0052750758.USD","LU0140636845.USD","LU0640798160.USD","HERO","BK4099","IE00BVYPNQ40.USD","BK4554","BK4565","IE0008368742.USD","BK4552","LU0651946864.USD","688235","LU0683595622.HKD","BK4575","LU0370786039.SGD","09626","LU1323998911.USD","LU1988902786.USD","LU0589944569.HKD","LU0708995583.HKD","LU0329678170.USD","06160","LU0501845795.SGD","LU0650527681.SGD","LU1115378108.SGD","LU1960683339.HKD","BK4579","LI","BK4509","BK4614","HK0000306701.USD","LU0738911758.USD","LU0823397103.USD","LU0823397285.USD","LU1868837722.USD","LU1993786604.SGD","02015","EVS.SI","IE00BGV7N243.SGD","LU2279858448.HKD","LU0880133367.SGD","ONC","LU0456842615.SGD","LU1008478684.HKD","JD","IE00BYV24P56.USD","BK4612","LU0994945656.USD","LU0049112450.USD","LU2039709279.SGD","BK4607","IE00BVYPNP33.GBP","PDDL","BIDU","LU0310800965.SGD","LU0072913022.USD","LU0531971595.HKD","LU0210526637.USD","BK4527","LU0244354667.USD","BK4504","LU1064131342.USD","BK4538","HK0000320223.HKD","LU0516422952.EUR","BK4526","LU0516422440.USD","LU0545039389.USD","LU1235294995.USD","BK4534","LU1282648689.USD","LU0348825331.USD","NERD","LU0067412154.USD","LU1808992512.USD","LU1956131251.USD","LU1051768304.USD","BK4505","LU1880383440.USD","LU0359201885.HKD","LU0143863784.USD","KJD","LU0259732245.USD","LU1152091754.HKD","LU2148611432.USD","LU0426417589.USD","LU1043141396.HKD","BK4085","BK4220","LU2264538146.SGD","BIDG","IE00BMCWC346.EUR","LU0128525689.USD","09888","BK4139","LU2226246903.HKD","BK4553","LU2257852520.SGD","IE00BF5LJ272.USD","LU1121112475.USD","BK4543","LU0329678337.USD","LU0359202008.SGD","LU2399975544.HKD","IE00B29SXG58.USD","BK4524","BK4535","LU1242518931.SGD","LU0348805143.USD","LU1981816686.USD","KBAB","LU0307460666.USD","LU1046422090.SGD","LU0823413587.USD","SG9999014674.SGD","BBYY","LU0106959298.USD","09999","LU1719994722.HKD","LU0502904849.HKD","LU0588546209.SGD","NTES","LU0348827113.USD","BK4574","LU1051769294.HKD","HK0000306685.HKD","BABW","LU1228905037.USD","SG9999002562.SGD","BK4551","BK4513","LU1303224171.USD","LU0348816934.USD","LU0456827905.SGD","LU1046421795.USD","LU0918141705.HKD","BK4122","LU0359201612.USD","LU1267930227.SGD","ONLN","LU0823413660.USD","LU0572944931.SGD","IE00BFMHRM44.USD","LU0661504455.SGD","LU0327786744.USD","LU0231483743.USD","LU0516423174.USD","LU1023057109.AUD","LU0455707207.USD","LU0052756011.USD","LU0633140560.USD","ESPO","BK4588","BABX","LU0326950275.SGD","BK4510","IE00B0JY6N72.USD","IE00BGHQDM52.EUR","LU0164865239.USD","LU0463099449.HKD","BABO","FDNI","LU1048588211.SGD","LU0348788117.USD","LU0117841782.USD","LU0072462343.USD","LU0143863198.USD","SG9999002463.SGD","LU0251143458.SGD","LU0320764599.SGD","BK4585","BK4602","LU0594300419.USD","ODDS","KBDU","HK0000165453.HKD","BK4555","LU0633140727.USD","LU1823568750.SGD","LU0821914370.USD","LU0823426308.USD","BABU","LU1794554557.SGD","IE0031814852.USD","LU0051755006.USD","BK4503","BK4587","LU0426412945.USD","LU0516422366.SGD","LU0979878070.USD","LU0823039010.USD","HK0000320264.USD","LU1770034418.SGD","LU1228905540.USD","LU0328353924.USD","LU0561508036.HKD","LU1515016050.SGD","LU2087589342.USD","LU1171460220.USD","LU2177674079.SGD","BK4502","LU2211817866.USD","LU2242644610.SGD","SG9999002828.SGD","LU0797268264.HKD","LU0918141887.USD","LU1961090484.USD","LU0039217434.USD","LU0737861772.HKD","LU0287142896.SGD","LU0417516902.SGD","BK4501","LU1105468828.SGD","LU1235295612.USD","LU1807302812.USD","LU1152091168.USD","LU1688375341.USD","BABA","LU0823038988.USD","LU0456846285.SGD","LU1769817179.HKD","LU0605514214.HKD","LU1048596156.SGD","LU1720050803.USD","LU0315179316.USD","LU1868837565.USD","LU2008162690.USD","BK4532","CLIX","LU0823426480.USD","DRAG","LU1188198961.HKD","LU0871576103.HKD","LU0651947912.USD","KWEB","LU0594300179.USD","LU1003077747.HKD","BK4548","LU0878005551.USD","BK4581","LU1769817096.USD","09988","BK4514","BK4533","IE00B3M56506.USD","ALBmain","BK4558","LU0047713382.USD","BK4531","LU1043141123.HKD","IE0034224299.USD","LU0348814723.USD","PDD","LU1868838027.USD","LU0048580855.USD","09618","LU0235996351.USD","LU0545562505.USD","KPDD","LU0949170772.SGD","BK4577","BK4077","LU1242518857.USD","LU1251922891.USD","BK4566","BILI","LU0516423091.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154829","title":"每周股票复盘：百济神州（688235）授出43.4万股受限股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154829","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650154829?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:01","pubTimestamp":1783792871,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，百济神州报收于267.84元，较上周的266.96元上涨0.33%。本周，百济神州7月6日盘中最高价报288.96元。百济神州当前最新总市值4128.54亿元，在化学制药板块市值排名1/149，在两市A股市值排名35/5202。本周关注点公司公告汇总：董事会薪酬委员会授出相当于434,044股股份的受限制股份单位，约占已发行股份总数的0.03%。公司公告汇总港股公告：证券变动月报表百济神州有限公司截至2026年6月30日，法定注册股本总额为231,146.38美元，每股面值0.0001美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1588","BK1161","LU1770034418.SGD","LU0307460666.USD","LU1251922891.USD","LU1969619763.USD","LU2328871848.SGD","LU1303224171.USD","BK0239","688235","BK1500","LU0588546209.SGD","06160","LU1719994722.HKD","KURE","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649020961","title":"百济神州(06160)授出合共3.34万股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2649020961","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649020961?lang=zh_cn&edition=full","pubTime":"2026-07-08 17:02","pubTimestamp":1783501342,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年7月2日，董事会薪酬委员会根据2016期权及激励计划的条款授予215名承授人合共3.34万股美国存托股份受限制股份单位。该等受限制股份单位相当于43.4万股股份，约占本公告之日公司发行股份总数的0.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","06160","BK4588","BK1583","LU0588546209.SGD","LU1719994722.HKD","BK1588","LU1770034418.SGD","BK4526","BK1161","LU1303224171.USD","688235","BK0239","LU1251922891.USD","LU0307460666.USD","LU2328871848.SGD","KURE","BK1500","BK4585","BK4139","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649607506","title":"百济神州：截至2026年3月31日股东户数为35,393户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649607506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649607506?lang=zh_cn&edition=full","pubTime":"2026-07-07 15:36","pubTimestamp":1783409766,"startTime":"0","endTime":"0","summary":"证券之星消息，百济神州07月07日在投资者关系平台上答复投资者关心的问题。请问截止6月18日，公司A股的股东人数是多少，谢谢！公司在已披露的2026年第一季度报告中公布，截至2026年3月31日，公司普通股的登记股东有35,385户和8户美国存托股份的记录持有人，合计35,393户。公司会在定期报告中面向所有投资者统一披露截至相应报告期末的股东户数，敬请关注公司定期报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700020780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1303224171.USD","688235","LU0588546209.SGD","LU1770034418.SGD","BK1583","BK1500","LU0307460666.USD","LU1719994722.HKD","LU1969619763.USD","BK0239","LU2328871848.SGD","KURE","06160","BK1588","BK1161","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649607885","title":"【券商聚焦】华福证券首予百济神州(06160)“买入”评级 指公司迈入多曲线增长新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649607885","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649607885?lang=zh_cn&edition=full","pubTime":"2026-07-07 15:25","pubTimestamp":1783409101,"startTime":"0","endTime":"0","summary":"实体瘤领域被视为公司的第二增长曲线，多款产品进入关键临床。首次覆盖，给予“买入”评级，目标价297.44港元，认为公司已迈入多曲线增长新纪元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985267","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","161027","06160","ONC","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649691717","title":"每周股票复盘：百济神州（688235）百悦泽临床研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2649691717","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649691717?lang=zh_cn&edition=full","pubTime":"2026-07-05 01:22","pubTimestamp":1783185731,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，百济神州报收于266.96元，较上周的232.1元上涨15.02%。本周，百济神州7月2日盘中最高价报268.88元。百济神州当前最新总市值4114.97亿元，在化学制药板块市值排名1/149，在两市A股市值排名34/5203。本周关注点公司公告汇总：百悦泽在套细胞淋巴瘤一线治疗3期临床研究MANGROVE达到主要终点PFS。公司公告汇总百济神州有限公司自愿披露其产品百悦泽在套细胞淋巴瘤成人初治患者一线治疗中的3期临床研究MANGROVE取得积极结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","LU1719994722.HKD","06160","LU1251922891.USD","688235","BK1583","BK1588","KURE","LU1770034418.SGD","LU0307460666.USD","BK0239","LU1303224171.USD","BK1500","LU1969619763.USD","LU2328871848.SGD","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648321346","title":"港股异动 | 百济神州(06160)早盘涨超4% MANGROVE 3期临床研究取得积极结果 计划下半年进行申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2648321346","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648321346?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:36","pubTimestamp":1783042590,"startTime":"0","endTime":"0","summary":"消息面上，近日，百济神州发布公告，MANGROVE 3期临床研究取得积极结果。MANGROVE是首个在该治疗场景下评估基于BTK抑制剂的无化疗方案对比标准免疫化疗方案的全球性、随机3期临床研究。该关键性3期临床研究的积极结果有望巩固泽布替尼在MCL疾病领域中的临床证据基础。百济神州计划在即将召开的医学大会上公布MANGROVE研究的完整结果，并正与全球监管机构就相关注册申报计划开展沟通，计划于2026年下半年进行申报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0307460666.USD","688235","BK4588","BK1161","BK4585","BK1588","BK1500","BK1583","ONC","BK4139","LU2328871848.SGD","LU1251922891.USD","LU1770034418.SGD","06160","BK4526","LU0588546209.SGD","LU1303224171.USD","BK0239","VXUS","LU1969619763.USD","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648559726","title":"百济神州补税风波：刚“摘U”即遇4.46亿元追缴，逾20家药企卷入，医药合规进入刚性时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2648559726","media":"华夏时报网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648559726?lang=zh_cn&edition=full","pubTime":"2026-07-01 13:52","pubTimestamp":1782885155,"startTime":"0","endTime":"0","summary":"4.46亿元补税计入2026年损益，刚刚扭亏为盈的百济神州，正在为一场突如其来的补税“埋单”。2026年6月27日，百济神州一纸公告引发关注：公司一家境内全资子公司需补缴税款及滞纳金合计约4.46亿元。而就在不久前，这家创新药龙头刚刚摘掉“未盈利”的标签，首次实现年度盈利，并上调全年业绩指引。但百济神州并非个案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607013790080574.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607013790080574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK1500","LU1969619763.USD","LU1719994722.HKD","LU2328871848.SGD","09939","BK4585","06160","688235","BK1583","LU1251922891.USD","BK0239","LU0588546209.SGD","LU1770034418.SGD","BK1161","BK1588","BK4526","BK1515","159938","LU0307460666.USD","BK1574","ONC","BK4588","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647551019","title":"百济神州最新公告：公司产品百悦泽3期临床研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2647551019","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647551019?lang=zh_cn&edition=full","pubTime":"2026-06-30 21:50","pubTimestamp":1782827419,"startTime":"0","endTime":"0","summary":"百济神州(688235.SH)公告称，公司产品百悦泽(泽布替尼胶囊)的3期临床研究MANGROVE取得积极结果。该研究评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗(BR)用于套细胞淋巴瘤(MCL)成人初治患者一线治疗。研究达到主要终点无进展生存期(PFS)，相较BR方案，百悦泽联合利妥昔单抗使疾病进展或死亡风险降低43%(HR=0.57)。公司计划于2026年下半年进行申报。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000045999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06160","BK1161","BK1588","LU1251922891.USD","LU2328871848.SGD","BK1500","BK1583","LU1303224171.USD","688235","LU1719994722.HKD","LU0588546209.SGD","LU1969619763.USD","LU0307460666.USD","LU1770034418.SGD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162318800","title":"百济神州将公布Mangrove研究完整数据 计划于2026年下半年提交全球监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1162318800","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162318800?lang=zh_cn&edition=full","pubTime":"2026-06-30 18:01","pubTimestamp":1782813686,"startTime":"0","endTime":"0","summary":"百济神州宣布，其Mangrove研究的完整数据即将公布。公司计划于2026年下半年向全球多个监管机构提交相关申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784868268384,"stockEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.195},{"period":"3month","weight":0.1601},{"period":"6month","weight":-0.0585},{"period":"1year","weight":0.1441},{"period":"ytd","weight":0.0143}],"compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0559},{"period":"3month","weight":-0.0498},{"period":"6month","weight":-0.0627},{"period":"1year","weight":0.0822},{"period":"ytd","weight":-0.0232}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35235人(较上一季度增加6.53%)","perCapita":"3265股","listingDate":"2021-12-15","address":"c/o BeOne Medicines I GmbH, Aeschengraben 27, 4051Basel, Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}